Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Our research

The research focus of the WA Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research focus of the The Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research of the The Kids Cancer Centre is undertaken by laboratory-based scientists, paediatric oncologists, computational biologists, and many higher degree (mainly PhD) and Honours students. Our research is organised into collaborative programs of laboratory-based and translational research.

Our goal is to discover new therapies - therapies that are more effective and less toxic - to fight the most aggressive cancers in babies and children. Our research focuses on:

  • Harnessing the power of the body's own immune system to fight cancer cells via immunotherapy.
  • Determining why apparently similar cancer cells from individual patients respond differently to treatment.
  • Testing existing drugs and new compounds to improve patient outcomes.
  • Understanding the biology of individual cancers to identify weaknesses to target with therapies.
  • Developing new treatments with industry partners to feed our drug development pipeline.

The WA Kids Cancer Centre has a game changing approach for fighting childhood cancer

Our research strategy is to use our world-first childhood cancer laboratory models to investigate potential new cancer immunotherapies and personalised medicines.

Immunotherapy is an exciting cancer treatment that works by engaging the body’s own immune response to fight the cancer. It promises to be an effective and safe cancer therapy that does not cause the collateral damage of conventional treatments. Immunotherapy has fulfilled this promise for adults with extraordinary results in some cancers. Sadly, the development of immunotherapy treatments for children falls far behind.

Personalised medicine involves performing detailed genetic analysis of individual children with cancer and using the information gained to treat them with drugs that are precisely targeted to the individual tumour. All children with cancer treated in Perth undergo such genetic testing, allowing us to use the genetics of individual’s tumours to inform both treatment development in the laboratory and clinical trial opportunities on the ward.

Our goal is to develop such promising and safe treatments to defeat childhood cancers and reduce the need for toxic chemotherapies and radiotherapies.

If you are interested in potential research collaborations, please contact us.

Latest

Videos

Abdominal Imaging at Initial Diagnosis and Following Relapse in Children With Acute Lymphoblastic Leukaemia

Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer-related death in children and adolescents. It is characterised by the proliferation of immature lymphoid cells capable of infiltrating bone marrow, blood and extramedullary sites. Five-year overall survival rates exceed 90% with current multidrug chemotherapeutic regimens. This manuscript reviews the abdominal imaging features of leukaemic infiltration in children with ALL at the time of initial diagnosis and following relapse.

Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1

Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors

CD8+ T cells are an important weapon in the therapeutic armamentarium against cancer. While CD8+CD103+ T cells with a tissue-resident memory T (TRM) cell phenotype are associated with favorable prognoses, the tumor microenvironment also contains dysfunctional exhausted T (TEX) cells that exhibit a variety of TRM-like features.

Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy

Osteoclasts are important regulators of bone remodeling, with an established role in maintaining skeletal homeostasis. The emergence of osteoimmunology has identified osteoclasts as key players in the immune system. In particular, osteoclasts can initiate bi-directional crosstalk mechanisms with hematopoietic stem cells and various immune cells, such as T cells, B cells and NK cells, to influence hematopoiesis and inflammatory response.

All publications